A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 12, 2021

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2027

Conditions

T-Prolymphocytic LeukemiaNon-Hodgkins Lymphoma

Interventions

DRUG

APG-115

QOD, 2 weeks on, 1 week off, in repeated 21-day cycles

DRUG

APG-2575

APG-2575 given orally each day in cycle, in repeated 21-day cycles

Trial Locations (3)

RECRUITING

Ohio State University, Columbus

RECRUITING

MD Anderson, Houston

RECRUITING

City of Hope, Duarte